Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of GAIA-102 alone and in combination for relapsed or refractory neuroblastoma and other pediatric solid tumors
jRCT2073220054Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2022
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GAIA-102 in neuroblastoma, rhabdomyosarcoma (RMS), undifferentiated sarcoma and 7 more (4 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity and Dose-limiting toxicity and adverse events. Started Nov 2022; status: recruiting.
02
Drugs
GAIA-102
03
Conditions
neuroblastomarhabdomyosarcoma (RMS)undifferentiated sarcomaEwing sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on jRCT2073220054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073220054.